Christopher A. Viehbacher - 01 Dec 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role: President and CEO, Director
Signature: /s/ Wendell Taylor, attorney-in-fact for Christopher A. Viehbacher
Issuer symbol: BIIB
Transactions as of: 01 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Dec 2022, 16:11:40 UTC
Previous filing: 21 Nov 2022
Next filing: 09 Feb 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIIB	Stock Option	Award	$0	+80,522		$0.000000	80,522	01 Dec 2022	Common Stock	80,522	$301.85	Direct	F1
transaction	BIIB	Restricted Stock Unit	Award	$0	+7,040		$0.000000	7,040	01 Dec 2022	Common Stock	7,040		Direct	F2, F3
transaction	BIIB	Performance Stock Unit	Award	$0	+45,998		$0.000000	45,998	01 Dec 2022	Common Stock	45,998		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Stock Options are eligible to vest and become exercisable in approximately equal annual installments on the first, second and third anniversaries of the grant date of December 1, 2022.
F2	Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock.
F3	Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022.
F4	This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.